Tag Archive for: open access

Posts

BJUI Compass new editor Michael Gorin

BJUI Compass – Announcing the new Editor-in-Chief

BJUI Compass is delighted to announce our new Editor-in-Chief, Michael A. Gorin, M.D.

Michael A Gorin, the new Editor-in-Chief of BJUI Compass

Michael A Gorin, the new Editor-in-Chief of BJUI Compass

Dr Gorin is an Associate Professor of Urology in the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai. He is an internationally recognized expert on the use of molecular imaging techniques in the diagnosis and management of urologic malignancies. He is also widely recognized for his work developing novel methods for performing MRI-guided transperineal prostate biopsy and focal ablative treatments for prostate cancer. As a fellowship-trained endourologist, Dr. Gorin’s clinical practice primarily focuses on caring for patients with kidney stones, lower urinary tract symptoms, and prostate cancer.

Dr. Gorin has published over 275 articles in peer-reviewed journals with collaborators from around the world. Additionally, he has contributed to multiple medical textbooks, including chapters in Campbell-Walsh-Wein Urology, The 5-Minute Urology Consult, and Gray’s Anatomy. In July 2022, Dr. Gorin was selected as the new Editor-in-Chief of BJUI Compass, the open-access companion journal to the BJU International. Dr. Gorin also serves on the editorial boards of several other journals, including UROLOGY (the Gold Journal), Urologic Oncology: Seminars and Original Investigations, and the World Journal of Urology. Dr. Gorin has received numerous honors and awards for his scholarly work, including the Drs. Carl and Barbara Alving Endowed Award for Outstanding Biomedical Research from the University of Miami Miller School of Medicine and the William F. Rienhoff, Jr., M.D. Scholar Award from Johns Hopkins University School of Medicine.

Dr. Gorin attended college at the University of Michigan, earning a Bachelor of Science in Cellular and Molecular Biology. He then attended medical school at the University of Miami Leonard M. Miller School of Medicine, where he graduated as an inductee to the Alpha Omega Alpha Honor Medical Society. Following medical school, Dr. Gorin completed a general surgery internship, urology residency, and fellowship in endoscopic and minimally invasive urology at the James Buchanan Brady Urological Institute at Johns Hopkins University School of Medicine.

 

Click here to find out more about BJUI Compass

 

BJUI Compass and open access

There is no doubt that the publishing landscape is rapidly changing around us. The BJUI is a world leading surgical journal, serving 10 international organisations, with 90 years of history (1929–2019). So why are we launching, BJUI Compass an online, open access (OA) journal, now?

In September 2018, cOAlition S, a predominantly European consortium of research funders, launched Plan S. In its current form, this plan requires that from 2021, scientific publications from research funded by public grants through funders who have signed up to cOAlition S must be published in full OA journals or platforms. This is a model whereby publication of science is paid for by authors, or their funders, rather than by readers to whom access is free [1]. The Wellcome Trust, one of the largest funders of research in the UK, is a major supporter of Plan S and has its own OA policy for 2021 [2].

However, the practical implementation of Plan S continues to be a subject of debate. In other parts of the world, there is increasing interest in OA but the approach to implementation is likely to vary considerably. Our own publisher, Wiley, in readiness for Plan S, announced an agreement with Projekt DEAL, a representative of nearly 700 academic institutions in Germany [3]. Most academic institutions in Germany under this project can publish articles in OA or hybrid journals published by Wiley, including BJUI, a hybrid journal. These initiatives in OA are another factor in the increasing debate about scientific impact, bibliometrics beyond the impact factor, and translating research for public benefit rather than purely the career progression of academics [4].

Dr John W. Davis (@jdhdavis)

 

In keeping with our continued theme of the highest quality, clinically relevant papers, in this issue of the BJUI we present two MRI‐based prostate cancer papers, showing that while we could avoid biopsies in many men without missing significant disease [5], in African‐American men on active monitoring, the cancers can be upgraded more frequently and careful follow‐up is thus warranted [6].

by Prokar Dasgupta and John W. Davis

 

References

  1. cOAlition SPlan S: Making full and immediate Open Access a reality. Available at: https://www.coalition-s.org/. Accessed October 2019
  2. WellcomeOpen access policy 2021. Available at: https://wellcome.ac.uk/funding/guidance/open-access-policy. Accessed October 2019
  3. WileyWiley and Projekt DEAL partner to enhance the future of scholarly research and publishing in Germany. Available at: https://newsroom.wiley.com/press-release/all-corporate-news/wiley-and-projekt-deal-partner-enhance-future-scholarly-research-an. Accessed October 2019
  4. Hicks DWouters PWaltman Lde Rijcke SRafols IBibliometrics: The Leiden Manifesto for research metrics. Nature 2015520429– 31
  5. Venderink Wvan Luijtelaar Avan der Leest M et al. Multiparametric magnetic resonance imaging and follow‐up to avoid prostate biopsy in 4259 men. BJU Int 2019124775– 84
  6. Bloom JBLebastchi AHGold SA et al. Use of multiparametric magnetic resonance imaging and fusion‐guided biopsies to properly select and follow African‐American men on active surveillance. BJU Int 2019124768– 74

 

Introducing The Urology Green List

henry-wooThe world of predatory scientific publishing had a major ‘win’ when Jeffrey Beall’s blog “Scholarly Open Access” was suddenly emptied of content in January 2017. Beall was tireless in his attempts to expose the unscrupulous behaviour of predatory open access journals whose objective was nothing other than to extract author publication charges (APCs) from unwitting academics. His blog was very much the “go to” site if one wished to check the legitimacy of a particular open access journal. In a confusing publishing landscape, it was an essential guidance on which open access journals were to be avoided. The growth of this predatory publishing industry has been exponential and clearly a reflection of the enormous amount money that is there to be made. Beall was constantly under attack from predatory publishers including threats of litigation. Beall has gone to ground and this normally vocal bastion of transparency has provided no reason for the sudden deletion of content from the Scholarly Open Access blog.

You can’t help to ask the following questions about the predatory publishing industry. How do these journals make such inroads into academia? How do they manage to outwit highly intelligent individuals to support their journal either through the submission of manuscripts or editorial board duties?  The answer is quite simple.  They prey on the naivety, vulnerability and egos of academics.

Spam email casts a wide net. Cast it wide enough and somebody is bound to get caught.  The standards required to publish articles in good journals has never been so high and the pressure to publish weighs heavy in the minds of academics.  These emails will always find an email inbox of a researcher on the rebound after the rejection of a manuscript from a reputable journal.  The language of the emails use flattery and an expert sales pitch to appeal to the recipient into submitting an article and then later discovering excessive APCs. If payment is refused, the article is published in any case; as a result of this action, they are deprived of the opportunity to submit their work elsewhere.

The same language is used to appeal to urologists to become members of editorial boards. Those accepting these roles unwittingly allow these journals to trade on their good name as well as the good name of their institutions to prop up their otherwise shonky image. These academics inadvertently contribute to the flow of manuscripts to these journals as a result of researchers associating the credibility of editorial board members with the credibility of the journal.

Beall’s focus was very much on where not to publish. The recent events suggest that a change in direction is needed. Accordingly, the Urology Green List has been created. The focus is all about good journals, both subscription and open access, where it is considered safe for the urological community to send their research for publication.  Beall demonstrated that it was a never ending task trying to keep up with an exponential growth in the numbers of predatory journals. It is far more practical to maintain a list of journals where it is safe to publish.

Absence from the list does not mean that a journal must be avoided – absence is nothing more than a red flag suggesting that there be appropriate due diligence in establishing the authenticity of the journal and to ask colleagues, friends and mentors for advice.

The Urology Green List will be a living on line document.  Visitors will be encouraged to make suggestions on which journals should be added to the list and which journals should be removed from the list.  In the near future, an International Editorial Board will be established to assist with providing opinion and review of journals that are for inclusion or exclusion from the Urology Green List.

In the longer term, a project will be to develop objective criteria for which journals on the Urology Green List may be assessed and graded.  In the future, it is hoped that researchers can be provided with guidance to understand the ‘best fit’ venue for their research amongst the journals that reside on the Urology Green List.

Please come and visit the Urology Green List.  It is here to support the urological community. Feedback is always welcome.

 

https://urologygreenlist.wordpress.com/

 

 

________________________

Henry Woo is a urological surgeon.  He is Professor of Surgery (Urology) at the Sydney Adventist Hospital Clinical School of the University of Sydney. He is also the Director of Uro-Oncology and Professor of Robotic Cancer Surgery at the Chris O’Brien Lifehouse cancer service in Sydney. @drhwoo

 

© 2024 BJU International. All Rights Reserved.